SCHEMBL25889014

SCHEMBL25889014

CNc1c(C#N)c(-c2ccc([N+](=O)[O-])cc2)nn1C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.42
ALDH1A1 P00352 2/20 0.40
RAB9A P51151 2/20 0.40
POLB P06746 2/20 0.40
LMNA P02545 1/20 0.40
DHODH Q02127 1/20 0.38
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
IKBKB O14920 1/20 0.36
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.36
KDM1A O60341 2/20 0.36
KDR P35968 1/20 0.35
CDK2 P24941 1/20 0.35
TLR2 O60603 1/20 0.34
TLR1 Q15399 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25888751 0.86 HTT (0.39) HTTALDH1A1RAB9APOLBLMNA
SCHEMBL25888754 0.83 HTT (0.41) HTTALDH1A1RAB9APOLBLMNA
SCHEMBL4257428 0.83 IKBKB (0.42) HTTALDH1A1RAB9APOLBLMNA
SCHEMBL30409113 0.83 MEN1 (0.42) HTTALDH1A1RAB9APOLBLMNA
SCHEMBL24133467 0.82 ADORA1 (0.47) HTTALDH1A1POLBLMNAMAPT
SCHEMBL30408688 0.81 POLB (0.36) HTTALDH1A1RAB9APOLBLMNA
SCHEMBL30409036 0.81 KDR (0.46) HTTALDH1A1RAB9APOLBLMNA
SCHEMBL30408211 0.81 ALDH1A1 (0.39) HTTALDH1A1RAB9APOLBLMNA
SCHEMBL25889159 0.81 POLB (0.36) HTTALDH1A1RAB9APOLBLMNA
SCHEMBL25889222 0.81 KDR (0.46) HTTALDH1A1RAB9APOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741018-A2 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-05-13 EP disclosed
US-12583836-B2 Sulphonamide compounds Anaxis Pharma Pty Ltd (AU) 2026-03-24 US disclosed
EP-4168401-B1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-01-07 EP disclosed
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-03-06 US disclosed
EP-4452966-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 EP disclosed
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 US disclosed
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 US disclosed
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 US disclosed
WO-2023115149-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 WO disclosed
EP-4168401-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-04-26 EP disclosed
CN-115956070-A Sulfonamide compounds 阿纳克西斯制药股份有限公司 2023-04-11 CN disclosed
WO-2021253095-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2021-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP9 HTT 3355/4885ALDH1A1 4680/4885RAB9A 1354/4885
US-12583836-B2 Sulphonamide compounds MLKL, RIPK3, CASP1 HTT 3278/4885ALDH1A1 4265/4885RAB9A 2712/4885
US-20230227429-A1 SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP1 HTT 3599/4885ALDH1A1 4663/4885RAB9A 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.